Survival Extension

In a presentation at the European Society for Medical Oncology, researchers reported that Roche's Perjeta (pertuzumab) could extend patients' lives, the New York Times reports.

According to lead researcher Sandra Swain from the MedStar Washington Hospital Center, patients who received the drug, which treats metastatic breast cancer, had a median survival time 16 months longer than those in the control group.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The New York Times profiles 23andMe's Anne Wojcicki and describes how she bounced back from a bad year.

Fotis Kafatos, the founding president of the European Research Council, has died, according to the Associated Press.

In PLOS this week: genomic analysis of honeybee disease, microRNA profiles of people with lupus nephritis, and more.

The Verge's Angela Chen tried out a gene test for fitness advice, but didn't learn much new information.